A patient recently asked me a question I hear more often than ever: “I exercise five days a week, eat well, my LDL cholesterol is controlled, so why did my CT scan show plaque?”
The answer wasn’t hidden in his lifestyle. It was in his genes.
His Lipoprotein(a), commonly written as Lp(a), was nearly four times the normal level.
Most people have never heard of Lp(a).
Yet approximately 1 in 5 people worldwide have high levels, placing them at significantly higher lifetime risk for heart attack, stroke, and aortic valve disease.
Unlike blood pressure, cholesterol, or blood sugar, Lipoprotein(a) is largely inherited. You don’t develop it because of poor lifestyle choices, and unfortunately, you can’t lower it simply by increasing your exercise or eating a healthier diet.
That makes it one of the most important, and most overlooked, cardiovascular risk factors.
What Exactly Is Lp(a)?
Think of Lp(a) as an LDL cholesterol particle with an extra protein attached to it called apolipoprotein(a).
That extra protein changes everything.
It makes the particle more likely to contribute to plaque buildup inside arteries and may also promote inflammation and thrombosis (blood clot formation).
In simple terms, Lipoprotein(a) doesn’t just increase cholesterol exposure; it makes plaque more dangerous.
This is why people with elevated Lp(a) can develop cardiovascular disease even when many of their other risk factors appear well controlled.
Why Haven’t Most People Been Tested?
Until recently, Lp(a) received relatively little attention. Part of the reason was practical.
For many years, there wasn’t a treatment specifically designed to lower Lipoprotein(a) so testing wasn’t routinely performed. That thinking has changed.
Today, major cardiovascular societies, including the American Heart Association, American College of Cardiology, European Society of Cardiology, and National Lipid Association, recommend measuring Lp(a) at least once during adulthood, especially in individuals with increased cardiovascular risk.
Why? Because knowing your Lipoprotein(a)level changes how we think about your lifetime risk and how aggressively we manage the risk factors we can modify.
Lifestyle Still Matters, Just Not in the Way You Think
One of the biggest misconceptions is that if Lp(a) is genetic, lifestyle doesn’t matter. Nothing could be further from the truth.
While healthy eating and regular exercise usually do not significantly lower Lipoprotein(a) itself, they absolutely reduce the impact of the other cardiovascular risk factors working alongside it.
Imagine Lipoprotein(a) as adding extra fuel to a fire. If blood pressure, diabetes, smoking, obesity, or elevated ApoB are also present, that fire burns much faster. Our goal is to remove as much additional fuel as possible.
Which translates to:
You may not be able to change your genes. But you can absolutely change the environment in which those genes operate.
Who Should Be Tested?
Although I believe awareness should be much higher, testing is particularly important if you have:
- A family history of premature heart disease
- A personal history of heart attack or stroke at a young age
- Elevated coronary artery calcium or coronary plaque that seems “unexpected”
- Familial hypercholesterolemia
- Aortic valve stenosis
- High ApoB despite treatment
In these situations, Lp(a) can provide an explanation that traditional cholesterol testing often misses.
I’ve cared for patients who exercised regularly, maintained healthy body weight, had acceptable LDL cholesterol, and still developed significant coronary artery disease.
Elevated Lp(a) helped explain why.
Why Lp(a) Matters Even More Than You Think
One reason Lp(a) is so important is that you only need to measure it once in most adults.
Unlike LDL cholesterol, which changes with diet, weight, medications, and lifestyle, Lp(a) levels remain relatively stable throughout life because they’re genetically determined.
That makes it a lifetime risk marker.
If your level is elevated at age 35, it’s likely to remain elevated at age 55 unless future Lp(a)-targeted therapies become widely available.
Knowing that information early allows physicians to be more proactive with the risk factors we can modify.
The Future Is Bright
Perhaps the most exciting development in preventive cardiology is that therapies specifically targeting Lipoprotein(a) are now in advanced clinical trials.
Several investigational medications have demonstrated reductions of 80–95% in Lp(a) levels.
The critical question, currently being studied, is whether lowering Lipoprotein(a) will translate into fewer heart attacks, strokes, and cardiovascular deaths.
If these outcome trials are successful, Lp(a) testing will likely become even more important in routine cardiovascular care.
We’re entering an era where identifying inherited cardiovascular risk may lead directly to personalized treatment.
The Pulse Perfect Perspective
One of the principles we emphasize at Pulse Perfect is that prevention should be proactive, not reactive. By the time chest pain develops, plaque has often been forming for decades.
Understanding inherited risk factors like Lp(a) allows us to personalize prevention much earlier. That doesn’t mean everyone needs advanced imaging or medication. It means making smarter decisions based on each person’s unique biology.
For someone with elevated Lipoprotein(a), we may place greater emphasis on aggressively controlling LDL cholesterol, optimizing ApoB, improving metabolic health, and considering additional cardiovascular assessment when clinically appropriate.
That’s precision prevention.
What I want you to take away
- Lipoprotein(a) is an inherited cholesterol particle associated with increased cardiovascular risk.
- About 20% of people have elevated Lp(a).
- A healthy lifestyle rarely lowers Lipoprotein(a), but it remains essential because it reduces overall cardiovascular risk.
- Most people only need Lp(a) measured once during adulthood.
- Elevated Lipoprotein(a)should prompt a more comprehensive discussion about cardiovascular prevention, not panic.
- New therapies specifically targeting Lipoprotein(a) are currently being evaluated in large clinical trials.
Final Thoughts
One of the greatest opportunities in modern preventive cardiology isn’t treating disease. It’s identifying risk before disease becomes symptomatic.
Lp(a) is a perfect example. You can’t choose your genetics. But you can choose what you do after learning about them.
Knowing your Lipoprotein(a) level won’t change your DNA. It can change your strategy. And sometimes, that’s the difference between reacting to heart disease and preventing it.
References
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: European Atherosclerosis Society Consensus Statement. Eur Heart J. 2022.
American Heart Association Scientific Statement on Lipoprotein(a). 2024.
2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia.
National Lipid Association Expert Clinical Consensus on Lipoprotein(a). 2024.
Tsimikas S. A Test in Context: Lipoprotein(a). J Am Coll Cardiol.
O’Donoghue ML, et al. Lipoprotein(a): Current Understanding and Future Therapies. Circulation.